CSL Behring Extends Support of World Federation of Hemophilia Programs

News provided by

Feb 04, 2019, 09:33 ET

Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness

MONTREAL and KING OF PRUSSIA, Pa., Feb. 4, 2019 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring today announced that the company has renewed its commitment as a Visionary Corporate Partner with WFH for another 3 years. CSL Behring was the first biotherapeutics leader to make a multiyear promise to WFH, an international not-for-profit organization that works to improve the lives of people with hemophilia and other inherited bleeding disorders. This is the company's fourth multiyear commitment to support critical WFH programs that help improve diagnosis and access to care for patients in developing countries, provide medical training, increase awareness, establish education initiatives and achieve government support through advocacy.

"We are grateful for the collaboration with our corporate partners like CSL Behring," said Alain Baumann, Chief Executive Officer, World Federation of Hemophilia. "Their support enables us to fulfill our commitment to the bleeding disorders community by providing valuable education, advocacy and access to WFH programs to patients and healthcare professionals, and to provide quality scientific data to further advance the understanding and care of hemophilia."

The agreement establishes CSL Behring as a "Leadership Partner" of WFH's Global Alliance for Progress (GAP) Program that aims to increase the diagnosis and treatment of patients with hemophilia and other bleeding disorders in developing countries. CSL Behring will also participate as a "Collaborating Partner" of the World Bleeding Disorders Registry (WBDR), the world's only global registry collecting standardized clinical data on hemophilia patients. In addition, CSL Behring will continue to be a significant contributor to the WFH Humanitarian Aid Program's efforts to provide consistent and predictable treatment access through product donations and financial support.

"We are proud to continue this longstanding relationship supporting these crucial WFH programs," said Jens Oltrogge, Head of Commercial Development Coagulation, CSL Behring. "All of these programs reinforce our promise to patients by empowering them through education and advocacy, raising awareness, advancing scientific knowledge and improving access to care."

In addition, corporate partnerships like this also help WFH increase awareness through efforts on World Hemophilia Day, 17 April, whose theme this year is "Reaching Out: The First Step to Care" focusing in outreach and identification as the first step to diagnosis and effective treatment.

About the World Federation of Hemophilia

For over 50 years, the World Federation of Hemophilia (WFH), an international not-for-profit organization, has provided global leadership to improve and sustain care for people with inherited bleeding disorders, including hemophilia, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders. Established in 1963, it is a global network of patient organizations in 140 countries and has official recognition from the World Health Organization. Visit WFH online at www.wfh.org.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX: CSL;USOTC: CSLLY), headquartered in Melbourne, Australia, employs more than 20,000 people, and delivers its life-saving therapies to people in more than 60 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.

SOURCE CSL Behring